A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K

Correlation of molecular alterations with efficacy of everolimus in hormone receptor–positive, HER2-negative advanced breast cancer: Results from BOLERO-2.

(2017) Gabriel N. Hortobagyi et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades

(2015) James Andrew McCubrey et al.   Oncotarget

Phase II Study of Temozolomide (TMZ) and Everolimus (RAD001) Therapy for Metastatic Melanoma

(2013) Roxana S. Dronca et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor

(2013) Jennifer A. Chan et al.   CANCER

Everolimus in Advanced Pancreatic Neuroendocrine Tumors: The Clinical Experience

(2013) J. C. Yao et al.   CANCER RESEARCH

Management of CNS-related Disease Manifestations in Patients With Tuberous Sclerosis Complex

(2013) Darcy A. Krueger   Current Treatment Options in Neurology

RTOG 0913: A Phase 1 Study of Daily Everolimus (RAD001) in Combination With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma

(2013) Prakash Chinnaiyan et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

mTORC1 couples immune signals and metabolic programming to establish Treg-cell function

(2013) Hu Zeng et al.   NATURE

Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities

(2013) Mariella Gruber Filbin et al.   NATURE MEDICINE

New agents in renal cell carcinoma

(2013) Raetasha Dabney et al.   Targeted Oncology

PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors

(2012) F. Meric-Bernstam et al.   CLINICAL CANCER RESEARCH

Molecular Therapies for Tuberous Sclerosis and Neurofibromatosis

(2012) David Neal Franz et al.   Current Neurology and Neuroscience Reports

Assessment of intra-observer variability in measurement of high-grade brain tumors

(2012) James M. Provenzale et al.   JOURNAL OF NEURO-ONCOLOGY

A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study

(2011) Warren P. Mason et al.   INVESTIGATIONAL NEW DRUGS

Diagnostic Usefulness of 3’-Deoxy-3’-[18F]Fluorothymidine Positron Emission Tomography in Recurrent Brain Tumor

(2011) Il Ki Hong et al.   JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY

3'-Deoxy-3'-18F-Fluorothymidine PET and MRI for Early Survival Predictions in Patients with Recurrent Malignant Glioma Treated with Bevacizumab

(2011) J. Schwarzenberg et al.   JOURNAL OF NUCLEAR MEDICINE

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

(2011) James C. Yao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neurofibromatosis-1 regulates mTOR-mediated astrocyte growth and glioma formation in a TSC/Rheb-independent manner

(2011) S. Banerjee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phase 3 trial of everolimus for metastatic renal cell carcinoma

(2010) Robert J. Motzer et al.   CANCER

North Central Cancer Treatment Group Phase I Trial N057K of Everolimus (RAD001) and Temozolomide in Combination With Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme

(2010) Jann N. Sarkaria et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

18F-FLT PET as a Surrogate Marker of Drug Efficacy During mTOR Inhibition by Everolimus in a Preclinical Cisplatin-Resistant Ovarian Tumor Model

(2010) N. Aide et al.   JOURNAL OF NUCLEAR MEDICINE

[18F]FLT PET for Non-Invasive Monitoring of Early Response to Gene Therapy in Experimental Gliomas

(2010) Maria A. Rueger et al.   MOLECULAR IMAGING AND BIOLOGY

PET for radiation treatment planning of brain tumours

(2010) Anca-L. Grosu et al.   RADIOTHERAPY AND ONCOLOGY

Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents

(2009) Terence O’Reilly et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Intra- and Interobserver Variability of Linear and Volumetric Measurements of Brain Metastases Using Contrast-Enhanced Magnetic Resonance Imaging

(2009) Hans-Christian Bauknecht et al.   INVESTIGATIVE RADIOLOGY

Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation

(2009) Tara Barwick et al.   NUCLEAR MEDICINE COMMUNICATIONS

PTEN Loss Does Not Predict for Response to RAD001 (Everolimus) in a Glioblastoma Orthotopic Xenograft Test Panel

(2008) L. Yang et al.   CLINICAL CANCER RESEARCH

Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177

(2008) Paul D. Brown et al.   JOURNAL OF CLINICAL ONCOLOGY